共 50 条
- [41] Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast CancerONCOLOGIST, 2023, 28 (05): : 414 - 424Zimmerman Savill, Kristin M.Ivanova, JasminaAsgarisabet, ParisaFalkenstein, AngelicaBalanean, AlexandrinaNiyazov, AlexanderRyan, Joanne C.Kish, JonathanGajra, AjeetMahtani, Reshma L.
- [42] Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Peng, PeijianXu, XiaoluZhong, JincaiYe, Jin-HuiWang, Zhi-HuiWang, HongLin, HongDu, CaiwenZou, GuorongOuyang, JieShi, Ying-yingXu, FeiYu, GengshengLu, YongkuiWang, Yong-XiaCui, Shi-EnLi, Lu-Zhen
- [43] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Tutt, Andrew Nicholas JamesKaufman, BellaGelber, Richard D.Mc Fadden, EleanorGoessl, Carsten DietrichViale, GiuseppeArahmani, AmalFumagalli, DeboraAzim, Hatem AbdelWu, WentingGrocholewicz, AnnaCostantino, Joseph P.Rastogi, PriyaGarber, Judy EllenGeyer, Charles E.
- [44] A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Sun, TaoShi, YanxiaCui, JiuweiYin, YongmeiOuyang, QuchangLiu, QiangZhang, QingyuanChen, YidingShao ZhiminWang, ShoumanWang, XiaojiaTong, ZhongshengZhong, YahuaYan, MinYan, XiWang, ChuanYang, HaiyuanLi, MiaoXiang, XiaoXu, Binghe
- [45] OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm)ANNALS OF ONCOLOGY, 2017, 28Tutt, A.Kaufman, B.Garber, J.Gelber, R.McFadden, E.Goessl, C.Viale, G.Geyer, C.Zardavas, D.Arahmani, A.Fumagalli, D.De Azambuja, E.Ponde, N.Herbolsheimer, P.Wu, W.Constantino, J.Rastogi, P.
- [46] Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)McCrea, CharlesHettle, Robert
- [47] BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC)ANNALS OF ONCOLOGY, 2017, 28Dalvi, T.Gelmon, K. A.Dent, R.Pegram, M.Loibl, S.Tazir, Y.Milner, A.Lewis, J.
- [48] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerONCOLOGY, 2023,Landry, Chrystal A.Blanter, JuliaRu, MengFasano, JulieKlein, PaulaShao, TheresaBhardwaj, AartiTiersten, Amy
- [49] Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic CancerJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3929 - +Kindler, Hedy L.Hammel, PascalReni, MicheleVan Cutsem, EricMacarulla, TeresaHall, Michael J.Park, Joon OhHochhauser, DanielArnold, DirkOh, Do-YounReinacher-Schick, AnkeTortora, GiampaoloAlguel, HanaO'Reilly, Eileen M.Bordia, SonalMcGuinness, DavidCui, KarenLocker, Gershon Y.Golan, Talia
- [50] Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian CancerONCOLOGY, 2024, 102 (01) : 9 - 16Landry, Chrystal A.Blanter, JuliaRu, MengFasano, JulieKlein, PaulaShao, TheresaBhardwaj, AartiTiersten, Amy